Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966593 | 0.90 | KDM4E (0.56) | KDM4EATMSTAT3SIGMAR1ABCB1 | |
| SCHEMBL9468333 | 0.87 | ATM (0.66) | KDM4EATMSTAT3ABCB1CYP19A1 | |
| SCHEMBL27817737 | 0.86 | STAT3 (0.51) | KDM4EATMSTAT3SIGMAR1ABCB1 | |
| SCHEMBL6780003 | 0.80 | STAT3 (0.57) | KDM4EATMSTAT3SIGMAR1ABCB1 | |
| SCHEMBL6774924 | 0.78 | EBP (0.50) | STAT3SIGMAR1ABCB1 | |
| SCHEMBL6049293 | 0.78 | DRD2 (0.43) | KDM4EATMSTAT3SIGMAR1ABCB1 | |
| SCHEMBL11497970 | 0.77 | SIGMAR1 (0.70) | STAT3SIGMAR1ABCB1ABCG2CYP19A1 | |
| Methylamine SCHEMBL10385050 | 0.77 | CYP19A1 (0.71) | KDM4EATMSIGMAR1ABCB1ABCG2 | |
| SCHEMBL8604705 | 0.77 | CYP19A1 (0.70) | KDM4EATMSIGMAR1ABCB1ABCG2 | |
| SCHEMBL30173445 | 0.77 | CYP19A1 (0.70) | KDM4EATMSIGMAR1ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KDM4E 452/4885ATM 4794/4885STAT3 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.